1 Result: Nivalis Therapeutics
Nivalis Therapeutics and Alpine Immune Sciences Agree to Combine
April 18th, 2017
- Plan to Accelerate Development of Novel Immunotherapies Focused on Inflammation and Immuno-Oncology - - Combined Company Well Capitalized with $90 Million in Funding to Advance Discovery and Development - - Existing Investors OrbiMed Advisors. Read more
Want To Find Some News?
News By Industries
April 29th, 2017April 28th, 2017April 27th, 2017